Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01915602
Title Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Bayer
Indications

hepatocellular carcinoma

Therapies

Refametinib + Sorafenib

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | BEL | AUT

Facility Status City State Zip Country Details
Louisville Kentucky 40202 United States Details
Wien 1090 Austria Details
Bruxelles - Brussel 1070 Belgium Details
Edegem 2650 Belgium Details
Leuven 3000 Belgium Details
Liege 4000 Belgium Details
Guangzhou Guangdong 510515 China Details
Beijing 100071 China Details
Shanghai 200032 China Details
Hradec Kralove 500 05 Czechia Details
Olomouc 775 20 Czechia Details
Bordeaux 33000 France Details
Caen Cedex 14033 France Details
Lyon 69004 France Details
Marseille 13005 France Details
Nice Cedex 3 06202 France Details
Paris 75012 France Details
Saint-priest-en-jarez 42270 France Details
Vandoeuvre-les-nancy 54511 France Details
Heidelberg Baden-Württemberg 69120 Germany Details
Tübingen Baden-Württemberg 72076 Germany Details
Frankfurt Hessen 60596 Germany Details
Essen Nordrhein-Westfalen 45136 Germany Details
Essen Nordrhein-Westfalen 45147 Germany Details
Magdeburg Sachsen-Anhalt 39120 Germany Details
Berlin 10967 Germany Details
Hamburg 20246 Germany Details
Hong Kong Hong Kong Details
Budapest 1062 Hungary Details
Debrecen 4032 Hungary Details
Pecs 7932 Hungary Details
Zalaegerszeg 8900 Hungary Details
Haifa 3109601 Israel Details
Jerusalem 9112001 Israel Details
Petach Tikva 4941492 Israel Details
Tel Aviv 64239 Israel Details
Bologna Emilia-Romagna 40138 Italy Details
Roma Lazio 00168 Italy Details
Milano Lombardia 20122 Italy Details
Milano Lombardia 20133 Italy Details
Nagoya Aichi 466-8560 Japan Details
Chiba-shi Chiba 260-8677 Japan Details
Fukuoka-shi Fukuoka 810-8563 Japan Details
Yokohama Kanagawa 241-8515 Japan Details
Osakasayama-shi Osaka 589-8511 Japan Details
Irima-gun Saitama 350-0495 Japan Details
Bunkyo-ku Tokyo 113-8655 Japan Details
Itabashi-ku Tokyo 173-8610 Japan Details
Kyoto 606-8507 Japan Details
Osaka 534-0021 Japan Details
Osaka 545-8586 Japan Details
Seoul Seoul Teugbyeolsi 08308 Korea, Republic of Details
Daegu 700-721 Korea, Republic of Details
Seoul 03722 Korea, Republic of Details
Seoul 05505 Korea, Republic of Details
Seoul 06351 Korea, Republic of Details
Seoul 06591 Korea, Republic of Details
Seoul 110-744 Korea, Republic of Details
Auckland 1023 New Zealand Details
Singapore 169610 Singapore Details
Santiago de Compostela A Coruña 15706 Spain Details
Oviedo Asturias 33011 Spain Details
Hospitalet de Llobregat Barcelona 08907 Spain Details
Vigo Pontevedra 36071 Spain Details
Madrid 28007 Spain Details
Madrid 28050 Spain Details
Bern 3010 Switzerland Details
Tainan 704 Taiwan Details
Tainan 736 Taiwan Details
Taipei 10002 Taiwan Details
Chiang Mai 50200 Thailand Details
Khon Kaen 40002 Thailand Details
Songkhla 90110 Thailand Details
Istanbul 34093 Turkey Details
Istanbul 34349 Turkey Details
Istanbul 34899 Turkey Details
Mersin 33070 Turkey Details
Birmingham B15 2TH United Kingdom Details
London SE5 9RS United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field